tradingkey.logo
tradingkey.logo
Search

Skye Bioscience Inc

SKYE
Add to Watchlist
0.675USD
-0.018-2.61%
Close 07/01, 16:00ETQuotes delayed by 15 min
23.72MMarket Cap
LossP/E TTM

TradingKey Stock Score of Skye Bioscience Inc

Currency: USD Updated: 2026-07-01

Key Insights

Skye Bioscience Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 186 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.71.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Skye Bioscience Inc's Score

Industry at a Glance

Industry Ranking
186 / 387
Overall Ranking
338 / 4564
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative-

Skye Bioscience Inc Highlights

StrengthsRisks
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 17.02M shares, decreasing 36.88% quarter-over-quarter.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
7.714
Target Price
+1012.69%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Skye Bioscience Inc?

The TradingKey Stock Score provides a comprehensive assessment of Skye Bioscience Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Skye Bioscience Inc’s performance and outlook.

How do we generate the financial health score of Skye Bioscience Inc?

To generate the financial health score of Skye Bioscience Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Skye Bioscience Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Skye Bioscience Inc.

How do we generate the company valuation score of Skye Bioscience Inc?

To generate the company valuation score of Skye Bioscience Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Skye Bioscience Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Skye Bioscience Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Skye Bioscience Inc.

How do we generate the earnings forecast score of Skye Bioscience Inc?

To calculate the earnings forecast score of Skye Bioscience Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Skye Bioscience Inc’s future.

How do we generate the price momentum score of Skye Bioscience Inc?

When generating the price momentum score for Skye Bioscience Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Skye Bioscience Inc’s prices. A higher score indicates a more stable short-term price trend for Skye Bioscience Inc.

How do we generate the institutional confidence score of Skye Bioscience Inc?

To generate the institutional confidence score of Skye Bioscience Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Skye Bioscience Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Skye Bioscience Inc.

How do we generate the risk management score of Skye Bioscience Inc?

To assess the risk management score of Skye Bioscience Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Skye Bioscience Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Skye Bioscience Inc.